. 2019 Dec 29;7(1):e000872. doi: 10.1136/bmjdrc-2019-000872

Table 5.

The impact of AMP-activated protein kinase (AMPK)-instrumented HbA1c reduction (%) on breast and prostate cancer using Mendelian randomization

Nine single-nucleotide polymorphisms	Data sets	Inverse variance weighting with fixed effects
Nine single-nucleotide polymorphisms	Data sets	OR	95% CI
Breast cancer (overall)	Breast Cancer Association Consortium	0.70	0.29 to 1.69
Breast cancer (estrogen receptor +ve)	Breast Cancer Association Consortium	0.77	0.27 to 2.20
Breast cancer (estrogen receptor −ve)	Breast Cancer Association Consortium	1.69	0.34 to 8.32
Breast cancer (overall)	UK Biobank	1.28	0.21 to 7.87
Prostate cancer	Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome consortium	0.60	0.19 to 1.85